In our series a mean of 5 units /cm2 was injected with a mean total dose of 48 units.
A mean total dose of 240 ± 35 MBq of the FDG was administered intravenously, which was computed as 4.2 ± 0.6 MBq/kg.
Mean total dose of midazolam was also reduced (17 vs 28 mg/kg, p = 0.05), and duration of sufentanil administration (112 vs 157 h, p = 0.05).
Conditioning included donor leukocyte infusions, target-specific irradiation, anti-T-cell antibody, cyclophosphamide, cyclosporine (CsA), followed by bone marrow (BM -derived and peripheral BM -derivedcell (PBSC) infusion into thymus, liver, BM, and peripheral with mean total dose of 20 × 108 nucleated cells/kg bloodweight (BW) (mean CD34+ count: 0.9%) pretranstemntation.
Scientific, San Diego, CA, USA) (2.5 to 5 mg/kg, total dose 7.5 to 22.5 mg/kg, mean total dose 12.7 ± 1.4 mg/kg), sustained seizure activity was induced for 4 h, while control rats (280 ± 9 g, N = 9) received saline injections (Table 1).
At the third cycle, the mean total dose was 64.0 vs. 63.3 MIU, respectively.
The mean total doses per subject was 2.4 for 6 months, and the mean monthly average dose per subject was 0.5.
The mean total doses of opioids (as morphine-equivalent dose) in the 24 hours preceding CE were 76 (87.5) mg, 3.3 (5.8) mg, and 43.3 (15.3) mg.
The mean total doses of propofol administered differed statistically between the two groups with a p-value of 0.02 (191.2 mg vs 172.1 mg, respectively).
The mean total doses to PTV-1, PTV-2 and PTV-3 were 76.2 Gy, 60.6 Gy and 51.3 Gy, respectively.
The mean total doses of breakthrough pain medication as a percentage of the mean daily consumption were 39.4% and 27.1% for hydromorphone and morphine in the IR phase, and 13.8% and 10.3% for OROS® hydromorphone and CR morphine in the SR phase.
